Clinical Trial Detail

NCT ID NCT02723955
Title Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors GlaxoSmithKline
Indications

bladder carcinoma

colorectal cancer

squamous cell carcinoma

melanoma

head and neck carcinoma

esophageal carcinoma

lung non-small cell carcinoma

malignant pleural mesothelioma

colon carcinoma

cervix carcinoma

prostate carcinoma

Therapies

GSK3359609

GSK3359609 + Pembrolizumab

Age Groups: child

No variant requirements are available.